Clarius Group, LLC Karuna Therapeutics, Inc. Transaction History

Clarius Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 29, 2024	SELL	$161.01 - $317.85 $4.83 Million - $9.53 Million	-29,973 Reduced 30.21%	69,248 $21.9 Million
Q2 2023 Aug 09, 2023	SELL	$176.32 - $240.22 $3.61 Million - $4.92 Million	-20,475 Reduced 17.11%	99,221 $21.5 Million
Q1 2023 Apr 17, 2023	BUY	$161.33 - $204.36 $1.5 Million - $1.9 Million	9,283 Added 8.41%	119,696 $21.7 Million
Q4 2022 Jan 25, 2023	BUY	$191.53 - $236.82 $85,613 - $105,858	447 Added 0.41%	110,413 $21.7 Million
Q3 2022 Oct 24, 2022	BUY	$123.79 - $277.42 $12.9 Million - $29 Million	104,514 Added 1916.98%	109,966 $24.7 Million

Q2 2022 Aug 10, 2022	BUY	$93.97 - $143.33 $512,324 - $781,435	5,452 New	5,452 $690,000

333K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Clarius Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Clarius Group, LLC with notifications on news.